TY - JOUR
T1 - Concurrent Chemo-radiation As a Means of Achieving Pathologic Complete Response in Triple Negative Breast Cancer
AU - Shafaee, Maryam Nemati
AU - Makawita, Shalini
AU - Lim, Bora
AU - Ellis, Matthew J.
AU - Ludwig, Michelle S.
N1 - Publisher Copyright:
© 2021 The Author(s)
PY - 2022/6
Y1 - 2022/6
N2 - Management of triple negative breast cancer (TNBC) that is resistant to chemotherapy remains a challenge. Many studies have investigated the unconventional approach of concurrent chemotherapy with radiation in management of TNBC that is resistant to neoadjuvant anthracycline and taxane containing chemotherapy. Various chemotherapies have been used as radiosensitizers. In this report we summarize the published literature and highlight clinical trials that pertain to management of TNBC.
AB - Management of triple negative breast cancer (TNBC) that is resistant to chemotherapy remains a challenge. Many studies have investigated the unconventional approach of concurrent chemotherapy with radiation in management of TNBC that is resistant to neoadjuvant anthracycline and taxane containing chemotherapy. Various chemotherapies have been used as radiosensitizers. In this report we summarize the published literature and highlight clinical trials that pertain to management of TNBC.
KW - Concurrent Chemo-radiation
KW - Pathologic complete response
KW - Primary resistant TNBC
KW - Triple negative breast cancer
UR - http://www.scopus.com/inward/record.url?scp=85124818386&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85124818386&partnerID=8YFLogxK
U2 - 10.1016/j.clbc.2021.12.001
DO - 10.1016/j.clbc.2021.12.001
M3 - Comment/debate
C2 - 35184934
AN - SCOPUS:85124818386
SN - 1526-8209
VL - 22
SP - e536-e543
JO - Clinical breast cancer
JF - Clinical breast cancer
IS - 4
ER -